Study Investigating the Effect of 4 Doses of RPL554 Given in Addition to Tiotropium to Patients With COPD

Condition:   COPD Interventions:   Drug: Ensifentrine (formerly RPL554) 0.375 mg twice daily plus placebo, in addition to tiotropium;   Drug: Ensifentrine (formerly RPL554) 0.75 mg twice daily plus placebo, in addition to tiotropium;   Drug: Ensifentrine (formerly RPL554) 1.5 mg twice daily plus placebo, in addition to tiotropi um;   Drug: Ensifentrine (formerly RPL554) 3.0 mg twice daily plus placebo, in addition to tiotropium;   Drug: Ensifentrine (formerly RPL554) placebo twice daily, in addition to tiotropium Sponsors:   Verona Pharma plc;   IQVIA;   LGC Limited Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials